Accuracy - the Crucial Factor
Accuracy — with Precision, Control, Effortless Penetration, Capture, Transport — the hummingbird is nature’s most skillful surgeon. TransMed7’s Zero5 technology leverages these principles to unlock the power of repeatable access to every area of the body to remove, reveal, deliver or replace. Enter the new frontier.
Who We Are And What We Do
TransMed7 is a privately-held medical technology company founded in 2010 to generate transformational technologies for diverse fields of healthcare around the world.
We are focused on the highly efficient development of innovative, cost effective, minimally invasive medical devices via several project companies with a particular focus in oncologic, regenerative, and cardiovascular disease.
Our products are designed to address critical healthcare needs in medical fields such as: breast health; soft tissue surgery, including small or fragile tissues and difficult to access areas; endoscopy, laparoscopy, robotics applications; bone marrow biopsy and harvest; interventional cardiology; and minimally invasive peripheral vascular procedures.
News & Announcements
TransMed7, LLC Announces First Results from Clinical Use of its Vacuum-Assisted, Single Insertion - Multiple Collection (SIMC™) Platform of Breast Biopsy Devices
TransMed7, LLC Announces 510(k) Clearance by the U.S. FDA for its Concorde US
(Ultrasound) and Concorde ST (Stereotactic) Soft Tissue Biopsy Device Platform
Pre-Production Test Devices of Heron’s “Zero5” Work Element Scaled to 18 Gauge and on Long (16 cm+) Needles Being Prepared
Prototypes for Cardinal, a Fine Needle Core Biopsy Device and VacuPac, a Portable External Vacuum Assist Device Shown at ASBrS
SpeedBird 38, Universal, and Universal 99 as well as Concorde Stereotactic (ST) and Concorde Ultrasound (US) “Soft” Launch Initiated at American Society Breast Surgeons (ASBrS)
Want to Know More?
please reach out to us using the form below.